Ascendis Pharma A/S ASND
250.88 USD +0.71 (+0.28%)
Nov 4, 2026, 9:56 AM EST
250.15 Day range 252.70
188.07 52-week range 282.15
- YTD
- +17.65%
- 1 year
- +20.48%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 305.02 +21.6% upside
Now 250.88
- Target (low)
- 261.81
- Target (mean)
- 305.02
- Target (high)
- 343.27
Ratings (0m) 21 20 buy · 1 hold · 0 sell
- Strong buy5
- Buy15
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 21
- 2 months ago 20
- 3 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.12 | 0.65 – 1.65 | 0.00 | 0.0% | 364.73M | +70.7% | 4 |
| Next quarter | 1.42 | 0.60 – 2.23 | 0.00 | 0.0% | 410.06M | +65.7% | 4 |
| Current year | 10.08 | 3.61 – 15.62 | 0.00 | 0.0% | 1.37B | +89.9% | 5 |
| Next year | 8.90 | 6.26 – 12.56 | 10.08 | -11.7% | 2.01B | +46.9% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 25, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 15, 2026 | Raymond James | Downgrade | Strong Buy | Outperform |
| Sep 2, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 1, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 1, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 31, 2026 | B of A Securities | Maintained | Buy | Buy |
| Aug 31, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 31, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 27, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Aug 14, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 19, 2026 | Citigroup | Initiated | — | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 11, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 16, 2026 | B of A Securities | Maintained | Buy | Buy |
| Apr 9, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 12, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 30, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jan 28, 2026 | Barclays | Initiated | — | Overweight |
| Jan 20, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
